Thromb Haemost 1999; 82(02): 801-805
DOI: 10.1055/s-0037-1615914
Research Article
Schattauer GmbH

Regulation of the Procoagulant Response to Arterial Injury

Mark B. Taubman
1   The Zena and Michael A. Wiener Cardiovascular Institute
,
Peter L.A. Giesen
2   Division of Thrombosis Research, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
,
Alison D. Schecter
1   The Zena and Michael A. Wiener Cardiovascular Institute
,
Yale Nemerson
2   Division of Thrombosis Research, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

Introduction

Thrombosis is commonly associated with arterial injury. Clinically, this is seen with all interventional procedures designed to treat coronary artery stenosis, such as percutaneous transluminal coronary angioplasty (PTCA),1 directional coronary, 1 atherectomy (DCA)2 and coronary artery stenting.3 Acute thrombosis occasionally results in total occlusion of the vessel lumen. However, more typical is the deposition of smaller nonocclusive mural thrombi.

Thrombosis is also a common feature of many animal models of arterial injury.4-8 These models have provided considerable information about the molecular events associated with injury-induced thrombus formation. Platelet adherence to the injured arterial wall occurs within minutes in all models of arterial injury. In some models, platelet deposition is followed by fibrin deposition, a consequence of activation of the coagulation cascade. The presence and extent of fibrin deposition varies with the degree of injury (superficial or deep), the type of vessel (carotid, femoral, aorta, or coronary), the state of the vessel prior to injury (normal, cholesterol fed, previously injured), and the species. In the pig carotid balloon injury model, endothelial denudation in the absence of medial injury is associated with platelet deposition but no fibrin generation. More severe injury, defined by the presence of a medial tear, results in marked platelet accumulation and fibrin generation, even in the presence of high doses of heparin.4,9 Unlike the porcine model, balloon injury to normal rodent arteries is associated with rapid platelet deposition but does not result in significant fibrin deposition, even in the presence of medial injury.5-8

In contrast to that found using normal arteries, fibrin deposition is seen when previously injured rabbit arteries, possessing a neointima, are subjected to a second injury.5,7,8,10 As determined by scanning and transmission electron microscopy, abundant fibrin formation is detected within 30 minutes of the reinjury. Platelet deposition is also more dense after the second injury and associated with fibrin-platelet microthrombi. We have recently found a similar difference between single and double injury in rat aorta and carotid arteries. These studies suggest that, in contrast to the deposition of platelets, which accompanies any injury to the arterial wall, the deposition of fibrin and the formation of large thrombi are more dependent on the type of injury produced and may be regulated by specific processes occurring in the arterial wall.

 
  • References

  • 1 I. Losordo DW, Rosenfield K, Pieczek A, Baker K, Harding M, Isner JM. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Circulation 1992; 86: 1845-1858.
  • 2 Carrozza Jr. JP, Baim DS. Complications of directional coronary atherectomy: incidence, causes, and management. Am J Cardiol 1993; 72: 47E-54E.
  • 3 Nath FC, Muller DW, Ellis SG, Rosenschein U, Chapekis A, Quain L, Zimmerman Topol EJ. Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. J Am Coll Cardiol 1993; 21: 622-627.
  • 4 Steele PM, Chesebro JH, Stanson AW, Holmes Jr. DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112.
  • 5 Stemerman BM. Thrombogenesis of the rabbit arterial plaque. Am J Pathol 1973; 73: 7-26.
  • 6 Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
  • 7 Groves MH, Rathbone-Kinlough LR, Richardson M, Jorgensen L, Moore S, Mustard FJ. Thrombin generation and fibrin formation following injury to rabbit neointima. Lab Invest 1982; 46: 605-612.
  • 8 Richardson M, Rathbone-Kinlough LR, Groves MH, Jorgensen LG, Mustard FJ, Moore S. Ultrastructural changes in re-endothelialized and non-endothelialized rabbit aortic neo-intima following re-injury with a balloon catheter. Br J Exp Path. 1984; 65.
  • 9 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665.
  • 10 Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost 1998; 80: 506-511.
  • 11 Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-184.
  • 12 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
  • 13 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-843.
  • 14 Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996; 75: 451-461.
  • 15 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-1232.
  • 16 Annex BH, Denning SM, Channon KM, Sketch Jr. MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
  • 17 Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 1997; 133: 213-219.
  • 18 Davies MJ, Thomas AC. Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373.
  • 19 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-318.
  • 20 Drake AT, Morrissey HJ, Edgington ST. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989; 134: 1087-1097.
  • 21 Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91: 2253-2259.
  • 22 Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK. et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63.
  • 23 Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995; 92: 3323-3330.
  • 24 Speidel CM, Thornton JD, Meng YY, Eisenberg PR, Edgington TS, Abendschein DR. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa. Coron Artery Dis 1996; 7: 57-62.
  • 25 Gallo R, Fallon JT, Toschi V, Gertz SD, Padurean A, Nemerson Y, Chesebro J, Fuster V, Badimon JJ. Bi-phasic increase of tissue factor activity after angioplasty in porcine coronary arteries. Circulation 1995; 92: I-354 (Abstract).
  • 26 Schecter AD, Fallon JT, Thiruvikraman SV, Taby O, Rosenfield CL, Rossikhina M, Nemerson Y, Taubman MB. Delayed surface expression of active tissue factor in human arterial smooth muscle cells determined by a novel in situ activity assay. Circulation 1995; 92: I-804.
  • 27 Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-3276.
  • 28 Carson SD. Manifestation of cryptic fibroblast tissue factor occurs at detergent concentrations which dissolve the plasma membrane. Blood Coagul Fibrinolysis 1996; 7: 303-313.
  • 29 Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-395.
  • 30 Le DT, Rapaport SI, Rao LV. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267: 15447-15454.
  • 31 Maynard JR, Heckman CA, Pitlick FA, Nemerson Y. Association of tissue factor activity with the surface of cultured cells. J Clin Invest 1975; 55: 814-824.
  • 32 Mulder AB, Smit JW, Bom VJ, Blom NR, Ruiters MH, Halie MR, van der Meer J. Association of smooth muscle cell tissue factor with caveolae. Blood 1996; 88: 1306-1313.
  • 33 Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100: 2276-2285.
  • 34 Fukuda C, Iijima K, Nakamura K. Measuring tissue factor (factor III) activity in plasma. Clin Chem 1989; 35: 1897-1900.
  • 35 Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
  • 36 Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, Mizuno Y, Oshima S, Saito T, Tsuji I, Kumeda K, Kamikubo Y, Nakamura S. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-259.
  • 37 Giesen PL, Rauch U, Bohrmann B, Kling D, Himber J, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: a new view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
  • 38 Mackman N. Regulation of tissue factor gene expression in human monocytic and endothelial cells. Haemostasis 1996; 26: 17-19.
  • 39 Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, Giesen PL, Nemerson Y, Taubman MB. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997; 272: 28568-28573.
  • 40 Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest 1993; 91: 547-552.
  • 41 Schecter SD, Giesen PLA, Fallon JT, Nemerson Y, Taubman MB. PDGF induces the release of active tissue factor (TF) from smooth muscle cells: a potential source of extracellular TF in the atherosclerotic plaque. Circulation 1997; 96: I-43A.
  • 42 Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, Masuda M, Takahashi H, Nomura S, Fukuhara S. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells [In Process Citation]. Thromb Res 1998; 91: 297-304.
  • 43 Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1177-1209.
  • 44 McNamara CA, Sarembock IJ, Bachhuber BG, Stouffer GA, Ragosta M, Barry W, Gimple LW, Powers ER, Owens GK. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost 1996; 22: 139-144.
  • 45 Ko FN, Yang YC, Huang SC, Ou JT. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest 1996; 98: 1493-1501.
  • 46 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-2320.
  • 47 Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992; 12: 948-954.
  • 48 Golino P, Ragni M, Cirillo P, D’Andrea D, Scognamiglio A, Ravera A, Buono C, Ezban M, Corcione N, Vigorito F, Condorelli M, Chiariello M. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998; 82: 39-46.
  • 49 Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050.
  • 50 Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis. 1996; 26 (Suppl. 01) 76-82.
  • 51 Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997; 96: 646-652.
  • 52 Marder VJ. Thrombolytic therapy: overview of results in major vascular occlusions. Thromb Haemost 1995; 74: 101-105.
  • 53 Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-1057.
  • 54 Drew AF, Davenport P, Apostolopoulos J, Tipping PG. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest 1997; 77: 291-298.